Kornimate/medical-research-clean huggingface dataset:
whole genome sequencing (chromoseq) as an adjunct to conventional genomic profiling in aml and mds

Conditions: Whole Genome Sequencing; Acute Myeloid Leukemia; Myelodysplastic Syndromes

Summary: this is a single institution, prospective study of the whole genome sequencing assay, chromoseq. using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing chromoseq in addition to standard genomic testing, for patients with the diagnoses of acute myeloid leukemia (aml) or myelodysplastic syndrome (mds).


Eligibility criteria:
inclusion criteria patient * patient with a clinical suspicion for a new diagnosis of aml or mds for whom the diagnostic molecular testing via the hematologic molecular algorithm (hma) at bjh is requested or planned to be requested. * adult patients 18 years or older. * ability to understand and willingness to sign an irb approved written informed consent document. inclusion criteria physician * treating physician at washington university school of medicine who directs therapy for individuals with hematologic malignancies. * able and willing to complete standardized questionnaires about usability, and stakeholder perceptions of chromoseq during the chromoseq implementation process. exclusion criteria patient * younger than 18 years of age exclusion criteria physician * does not treat patients at washington university school of medicine
storytelling with or without social contextual information in children with autistic spectrum disorder and typical development

Conditions: Autism Spectrum Disorder; Healthy

Summary: this study was to examine the effects of storytelling with or without contextual information on children with autism spectrum disorder (asd) and typical development (td).

this was a 2 x 2 x 2 randomized controlled trial with 52 children (26 with asd and 26 with td) recruited in the community and randomized into four groups: 1) asd group 1 - storytelling with contextual information; 2) asd group 2 - storytelling without contextual information; 3) td group 1 - storytelling with contextual information; 4) td group 2 - storytelling without contextual information. all stories were photo-based and static in nature. the only difference between group 1 and group 2 was that the stories included and did not include social contextual information, respectively. training was delivered in small groups, with eight sessions across four weeks, two sessions per week, and 30 minutes per session. participants' total fixation duration (tfd), total visit duration (tvd), and total fixation count (tfc) on human faces from 20 photos and a video were recorded using the tobii eye tracker.

Eligibility criteria:
inclusion criteria for children with asd: * 1) children aged between 6 and 12 years old; * 2) had a previous diagnosis of asd from medical professionals; * 3) studied in mainstream primary school; * 4) had a composite iq score of 80 or above inclusion criteria for children with td: * 1) children aged between 6 and 12 years old; * 2) had no developmental disorder or intellectual disability; * 3) attended primary school. exclusion criteria: * na
decision aid and thyroid nodules management

Conditions: Thyroid Nodule

Summary: patients with small favorable malignant or indeterminate thyroid nodules will receive information about management of thyroid nodules. participants will be asked to complete brief surveys at the time of enrollment, shortly after the consultation appointment with the surgeon, and a few months after either the consultation or the surgery, to assess their satisfaction with their decision and decision making process. all participants will receive routine care and counseling by their endocrinologist and surgeon.


Eligibility criteria:
inclusion criteria: * histology showing indeterminate or malignant thyroid pathology (bethesda iii-vi) * thyroid nodule size less or equal to 2cm exclusion criteria: * history of thyroid surgery * history of thyroid cancer
clinical study on the treatment of hypertensive intracerebral hemorrhage with panax notoginseng saponin

Conditions: Hematoma Absorption and Neurological Function Recovery

Summary: the purpose of this study is to determine whether panax notoginseng saponins are effective in the treatment of hypertensive intracerebral hemorrhage patients.

patients with hich were randomly assigned to receive either pns integrated with conventional therapy. patients were treated with conventional therapy for 3 days, then plus pns for 14 days. patients in the control group received conventional therapy for 17days. hematoma volume measured by ct scanning, national institutes of health stroke scale (nihss) scores, barthel index (bi), all the three were used to evaluate the therapeutic effect for both groups after two weeks of intervention.

Eligibility criteria:
inclusion criteria: * with a history of hypertension treated with medication and blood pressure management ( a systolic blood-pressure target of 140 to 179 mmhg and a diastolic blood-pressure target of 70 to 100 mmhg) during the period of hospitalization, * the site of hematoma located in one of the cerebral hemispheres, * hematoma volume 10-30ml, * no blood in the ventricles, * within 24 hours of onset of first-time acute intracerebral hemorrhage, * no loss of consciousness (drowsiness acceptable). exclusion criteria: * cerebellar or brainstem hemorrhage, * intracerebral hemorrhage caused by bleeding diathesis, aneurysms, vascular malformations, improperly using anticoagulant drugs, or suspicious amyloid angiopathy, * subarachnoid hemorrhage; multifocal hemorrhage, * mixed stroke or hemorrhagic infarct, * coexisting systematic diseases such as heart or kidney failure, tumors, gastrointestinal hemorrhage and so on, * pregnant or lactating women, * a history of xuesaitong injection anaphylaxis.

Keywords: panax notoginseng saponins hypertensive intracerebral hemorrhage hematoma neurological function
exenatide on gi motor function and permeability in short bowel syndrome

Conditions: Short Bowel Syndrome

Summary: we plan to examine the gastrointestinal (gi) physiologic profile of exenatide, a glucagon-like peptide (glp-1) analog as a possible intestino-trophic growth factor capable of inducing small bowel adaptation and regeneration in patients with short bowel syndrome (sbs), with the potential to decrease parenteral nutrition dependence.


Eligibility criteria:
patients with short bowel syndrome, between the ages of 18-85 who are dependent on parenteral nutrition for at least a year and are being closely followed by the mayo clinic home parenteral nutrition program (hpn) with at least one multisystem evaluation a year.
air pollution, inflammation and acute coronary syndrome

Conditions: Patients With Acute Coronary Syndrome

Summary: the objectives of this study are: 1) to determine whether patients with acute coronary syndrome, the level of environmental exposure to particulate air pollutants in the week prior to admission, are related to concentrations of inflammatory molecules and oxidative stress. 2) to investigate whether the level of environmental exposure is an independent prognostic factor in terms of overall and cardiovascular mortality, myocardial infarction or unstable angina at 30 days, 6 and 12 months.


Eligibility criteria:
inclusion criteria: * patients with acute coronary syndrome exclusion criteria: * infectious process and / or local or systemic inflammation in the 15 days before admission. * thyrotoxicosis. * neoplasms - or any other disease that seriously compromise the prognosis of life and / or generate a systemic inflammatory response.

Keywords: acute coronary syndrome air pollution. inflammation. oxidative stress. prognosis
a study to characterize the pharmacokinetics of da-8031 in healthy male subjects

Conditions: Premature Ejaculatory Dysfunction

Summary: this is a dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation study. the study is designed to describe the relationship between multiple doses and pharmacokinetic parameters of da-8031 as well as safety profile.


Eligibility criteria:
inclusion criteria: * 20-45 years healthy male subjects * body weight :60-90kg, bmi between 18.5-25 exclusion criteria: * show sbp(systolic blood pressure) =\ =140mmhg, or dbp(diastolic blood pressure)=\ =90mmhg, or tachycardia (pr(pulse rate)\>=100times/min) * have a history of drug abuse or show positive for drug abuse or cotinine at urine screening * smokers
yoga-based rehabilitation program in reducing physical and emotional side effects in patients with cancer

Conditions: Alopecia; Anxiety; Breast Carcinoma; Cognitive Side Effects of Cancer Therapy; Colorectal Carcinoma; Depression; Fatigue; Lung Carcinoma; Nausea and Vomiting; Pain; Psychological Impact of Cancer; Sleep Disorder; Weight Change

Summary: this clinical trial studies yoga-based rehabilitation in reducing physical and emotional side effects of living with cancer or its treatment. yoga-based rehabilitation may reduce side effects and improve the quality of life of patients with breast, lung, or colorectal cancer.

primary objectives: i. to evaluate the effects of yoga on quality of life (qol) of breast cancer patients on different treatment regimens. ii. to pilot the effects of a yoga-based rehabilitation program versus standard care on qol impairment reported by newly diagnosed (a) lung and (b) colorectal patients. iii. to evaluate program compliance and satisfaction among breast, lung and colorectal cancer patients as well as among the various sociocultural subgroups (e.g., ethnicity, language). outline: participants are randomized to 1 of 2 arms. group i (yoga-based rehabilitation program): participants undergo a yoga-based rehabilitation program up to 5 days a week for 1.5 hours and practice at home at least once daily for 12 weeks. group ii (standard care/control): after a 3 month wait period, participants undergo yoga-based rehabilitation program as in group i.

Eligibility criteria:
inclusion criteria: * have been diagnosed with breast, lung or colorectal cancer in the previous 8 weeks * are to receive oncologic care at the albert einstein cancer center (aecc) * have a life-expectancy of at least 6 months * are either english- or spanish-speaking * do not practice yoga regularly (\> 1 month) * receive medical clearance by oncologic personnel on the study exclusion criteria: * eastern cooperative oncology group performance status \>= 3 * existence of any of the following: * seizure disorder * musculoskeletal conditions * heart problems * major psychiatric disorder
promoting resilience in stress management (prism) and clinical-focused narrative (cfn) pilot in adults with primary mitochondrial disease (pmd).

Conditions: Mitochondrial Diseases; Mitochondrial Myopathies; Mitochondrial Encephalomyopathies; MELAS; MERRF

Summary: the goal of this study is to find the best way to help people with primary mitochondrial disease deal with the stress of their condition, and to help these people be better able to "bounce back," or be resilient. in order to do this, the investigators are going to test two interventions (an intervention means that it aims to change something): promoting resilience in stress management (prism) and clinical-focused narrative (cfn) intervention.

the investigators are going to test two interventions in this pilot study. the first is called promoting resilience in stress management (prism). the second is called clinical-focused narrative (cfn) intervention. these interventions involve talking with the researcher about several specific topics. participants will join six virtual study visits. they will be assigned to the prism group or the cfn group. during the first study visit, participants will learn about the study and will fill out consent forms if they want to participate. in the next four visits, participants will receive one of the study interventions (prism or cfn). some interventions will be supported with a digital app for participants to track progress and review what was talked about in the intervention. the sixth virtual study visit will be a discussion group that happens a couple months after participants finish the intervention. participants will also be sent several surveys to complete. one set of surveys is sent just once after the participant enrolls in the study. another set of surveys is sent after the participant enrolls and again after the participant finishes the interventions. the study team will review participants' medical records to confirm they have primary mitochondrial disease and to review the genetic diagnosis. if participants do not have copies of their own medical records or if the study team does not already have access to them, the study team will ask participants to sign a release form to obtain a copy of the medical records and/or genetic testing report.

Eligibility criteria:
inclusion criteria: 1. males or females at least 18 years old 2. capable of giving consent, or there is a legally authorized representative capable of giving consent on the subject behalf and if appropriate, assent. 3. able to speak and read english 4. able to participate in web- and app-based interventions 5. confirmed molecular diagnosis of primary mitochondrial disease exclusion criteria: 1. suspected but no molecular diagnosis primary mitochondrial disease
lidocaine on manifestations of fibromyalgia

Conditions: Fibromyalgia; Chronic Pain

Summary: background and objectives: fibromyalgia is a pain syndrome characterized by numerous manifestations. the objective of this study was to evaluate the effect of the combination of intravenous lidocaine and amitriptyline on the manifestations of fibromyalgia. methods: a prospective, randomized, double-blind, comparative study was conducted. all patient received 25 mg amitriptyline. patients of group 1 (n = 15) received 125 ml 0.9% saline, and patients of group 2 (n = 15) received 240 mg lidocaine in 125 ml 0.9% saline once a week for 4 weeks. manifestations were recorded before and 4 weeks after treatment. pain intensity was rated on a verbal numerical scale.

amitriptyline was chosen in the present study because it is the most widely used antidepressant with proven analgesic efficacy for the treatment of a variety of chronic pain syndromes. amitriptyline also promotes improvement of sleep, an effect observed in the present study. lidocaine has been widely applied by the intravenous route and patients with a variety of pain syndromes, including fibromyalgia, have reported pain relief with this technique.the dose of lidocaine employed by various investigators ranges from 1 to 5 mg/kg administered over a period of 30-60 min. the minimum effective dose is 1.5 ml/l, which is achieved with 2-5 mg/kg infused over 30-60 min. in these study, 240 mg lidocaine was administered, corresponding to about 3 mg/kg.

Eligibility criteria:
inclusion criteria: * pain in the four quadrants of the body for at least 3 months * sleep disorders * fatigue * subjective edema * depression * paresthesia. exclusion criteria: * alterations in thyroid * rheumatological * renal and hepatic function * trauma * rheumatic, neuromuscular or psychiatric disease * infectious arthropathy * other pain syndromes * drug hypersensitivity * pregnancy

Keywords: lidocaine; fibromyalgia signs symptoms
examining the impact of blood flow restricted aerobic exercise on pgc-1α mrna expression in young healthy males

Conditions: Mitochondrial Biogenesis

Summary: this crossover study investigates the effects of restricting arterial blood flow during cycling exercise on pgc-1α and its upstream signalling pathways. in a randomized order, participants will exercise once for 30 minutes with restricted blood flow and then will exercise once for 30 minutes with no blood flow restriction.


Eligibility criteria:
inclusion criteria: * 3 hours of physical activity per week * no previous cycling training * no concurrent involvement in another training program * body mass index \< 30 kg/m2 exclusion criteria: * presence of cardiovascular disease * presence of metabolic disease * taking regular oral medication * current smoker

Keywords: acute exercise mitochondria skeletal muscle pgc1α mitochondrial biogenesis intracellular signalling
virtual reality cognitive therapy for alzheimer's disease

Conditions: Alzheimer Disease

Summary: to evaluate the usability, feasibility, and acceptability of vrct iteratively on 36 ad/adrd individuals with mild to moderate ci.

alzheimer's disease (ad) and alzheimer's disease-related dementias (adrd) resulting in cognitive decline affects more than 5.8 million americans. given the impact on quality of life, there is a great need for therapies focused on cognition. in this study, we will test the feasibility, usability, and acceptability of a novel virtual reality cognitive therapy (vrct) for ad developed by claritytek, inc. the vrct will focus primarily on skills that impact instrumental activities of daily living (e.g., taking medications, shopping). thirty-six individuals with mild to moderate ad/adrd will be enrolled and will utilize the vrct over seven weeks within their home. enrollment will occur in cohorts of 12 individuals, so that the vrct can be revised and optimized based on the results, prior to the next cohort. we will also hold expert focus groups with clinician specialists to obtain feedback for improvement.

Eligibility criteria:
inclusion criteria: * diagnosis of mild cognitive impairment (mci), probable alzheimer's disease (ad) or alzheimer's disease related dementias (adrd) * montreal cognitive assessment (moca) score of 11-25 * age 30-89 exclusion criteria: * non-english speaking * history of seizure disorder, vertigo disorder, or severe motion sickness that would impact their ability to participate in the intervention * history of any other serious condition that may limit their ability to participate in the intervention, as determined by the investigators. * inability to use the vr device (e.g., severe visual/hearing impairment, aphasia, facial injuries)
effect of two different doses of dexmedetomidine infusion in morbidly obese patients

Conditions: Anesthesia; Obesity, Morbid; Dexmedetomidine

Summary: compare the effects of two different doses of dexmedetomidine infusion on oxygenation as a primary outcome and on lung mechanics, quality of recovery and perioperative analgesia as secondary outcomes in morbidly obese patients with restrictive lung disease undergoing abdominal surgery.

dexmedetomidine is a selective α2 receptor agonist and has sympatholytic, analgesic, anti-inflammatory and sedative properties. dexmedetomidine decreased dead space and improved both lung compliance and oxygenation in chronic obstructive pulmonary disease (copd) patients undergoing lung cancer surgery. the effects of dexmedetomidine on oxygenation and lung mechanics had been investigated in obstructive lung disease, but there are little information about its effect in morbidly obese patients with restrictive lung disease .

Eligibility criteria:
inclusion criteria: * body mass index above 40 kg/m2 with restrictive lung disease((forced vital capacity) \<70% in pre-operative pulmonary function tests), of american society of anesthesiologists (asa) physical status ii and iii. * aged 18-50 years. * scheduled for abdominal surgery. exclusion criteria: * patients with forced expiratory volume1/forced vital capacity\<7. * uncontrolled cardiac, respiratory, hepatic or renal diseases. * allergy to the study drug
parathyroid auto-transplantation: prospective randomized trial of the personalized site

Conditions: Parathyroid Autologous Transplantation

Summary: the functional parathyroid auto-transplantation (pa) could release parathyroid hormone (pth) into the circulatory system of the body through the capillaries. but when parathyroid glands were auto-grafted in the sternocleidomastoid muscle, it would be inconvenient to detect pth to examine whether the graft functions. so the investigators took the forearm as the aim place for auto-transplantation, either subcutaneous or brachioradialis, with its relatively fixed - antecubital vein blood test which is simple. the survival criteria is assumed as the pth gradient of 1.5 times or greater through comparing the bilateral pth value in grafted and not-grafted forearm.


Eligibility criteria:
inclusion criteria: * patients with indications for pa treatment during cervical surgery exclusion criteria: * patients suffering secondary hypoparathyroidism with forearm fistulization

Keywords: parathyroid autografting thyroidectomy survival rate hypoparathyroidism
a follow-up study of immune dysregulation in patients with covid-19

Conditions: COVID-19; Immunosuppression

Summary: in order to detect the immunosuppression status of covid-19 patients, this study collected blood samples of covid-19 patients on the 10th, 20th and 30th days after the onset of symptoms, and detected the proinflammatory, anti-inflammatory factors，immunosuppressive marker，immune cells in the blood samples to evaluate the immunosuppression status of covid-19 patients.

after sars-cov-2 infection, the patient's immune system is overactivated. while the immune cells release a large number of proinflammatory factors, anti-inflammatory response starts at the same time. anti-inflammatory factors such as il-4, il-10, and il-37 will be compensated to resist the release of proinflammatory factors and prevent the further development of systemic inflammatory response. however, when the anti-inflammatory factor is excessively released, it will cause compensatory response syndrome, leading to immunosuppression. whether the level of anti-inflammatory factors continues to rise, and whether it will lead to the persistence of later immunosuppression is unknown. therefore, this study intends to recruit covid-19 patients, detect the pro-inflammatory and anti-inflammatory factors，immunosuppressive marker，immune cells in 10 days, 20days, and 30days after the symptoms appear, and evaluate the immunosuppression status of patients with covid-19

Eligibility criteria:
inclusion criteria: 1. participant is diagnosed with symptomatic covid-19 by a positive pcr for sars-cov-2 or antigen quicktest. 2. study participant is 18 years of age or older exclusion criteria: 1. patients with immunosuppression, including hiv infection, hematopoietic stem cell transplantation and high-dose immunosuppressant therapy 2. pregnancy or breastfeeding 3. patients receiving chemotherapy or other cancer treatment
dermacyd infantile (lactic acid) - photo evaluation.

Conditions: Hygiene

Summary: primary objective: to demonstrate the absence of photo irritation and photosensitization potential of the product dermacyd infantile (lactic acid).


Eligibility criteria:
inclusion criteria: * phototype skin i, ii, iii and iv * integral skin test in the region * willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion. exclusion criteria: * use of anti-inflammatory, immunosuppressant or anti-histaminic drugs * lactation or gestation * use of anti-inflammatory drugs 30 days and/or immunosuppressant drugs during 3 months before the selection * diseases which can cause immunity decrease, such as hiv, diabetes * previous atopy * history of sensitivity or irritation for topic products * active cutaneous diseases which can interfere in the study results * use of new drugs and/ or cosmetics during the study * cutaneous reactivity * previous participation in studies, which had used the product * volunteers who have immunodeficiency congenital or acquired. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.